Correction may set in anytime, warns Ambareesh Baliga

Published on Tue, Jan 24, 2012 at 15:33 |  Source : CNBC-TV18

Updated at Wed, Jan 25, 2012 at 08:20  

110701 Investors following Larsen. Share this News with them.
0
0
Share on Tumblr
Ambareesh Baliga, COO, Way2Wealth

Excerpts from Midcap Radar on CNBC-TV18 Watch the full show ยป

ALSO READ

The 50 bps cash reserve ratio (CRR) cut by the Reserve Bank of India has given a boost to the Indian market. However, Ambareesh Baliga, COO of Way2Wealth says, the rally may not last too long. 'I think we are more or less close to the top and the correction may set in anytime,' he adds.

Although Baliga is cautious on the market now, he says it will only be a correction and the market will not re-enter the bear phase.

According to him, any sort of correction should be utilised to buy. 'I would be looking at buying into banks. I would be looking at buying capital goods, autos, everything other than FMCG, realty and pharma,' he adds.

Also read: Be choosy while picking bank stocks, says Tata Invst Corp

Below is the edited transcript of his interview with CNBC-TV18's Sonia Shenoy and Gautam Broker. Also watch the accompanying video.

Q: Do you think people can still buy into this rally, given the kind of fundamentals change we have had in terms of the overall macro economic policy or would you still be cautious?

A: At these levels, I would be a bit cautious, especially from a fundamental buy point of view. I don't see this bump up, which we have got today, lasting too long because the rally in last two-three days seems to be have been a bit overdone. We were not really expecting a repo cut, but the thumbs up, which the market has given to the CRR cut, may not last too long.

Q: It has been quite an uninterrupted move in the market. But up until what level would you be comfortable? Beyond what point would you start getting cautious on the market now?

A: Even earlier we were saying that the markets may not last too much beyond 5,050-5,100. Because of today's policy, we have seen bump up beyond those levels. I think we are more or less close to the top and the correction may set in anytime. That correction could also be led by some of the results which we will see in the next few days. We have noticed, in the past few years, that the results which come towards the last seven-ten days tend to disappoint the markets as compared to the results which we have seen in the last 15 days. The next few results may not enthuse the markets.

Q: Things are really changing for the interest rate sensitives. We actually have the reversal in place now. Even if your call is the markets could have topped out for the moment and could decline, what would you be looking to buy on declines from the rate sensitives?

A: I have been maintaining all through in the last few weeks, it will only be a correction; we will not re-enter the bear phase. So, any sort of correction should be utilised to buy. Clearly I would be looking at buying into banks. I would be looking at buying capital goods, autos, everything other than FMCG, realty and pharma.

Q: We were talking about L&T as well post the numbers, but that stock has moved another 5% today. What is the call on the stock now? Where do you see it headed from here?

A: If you are talking of fundamental call over a longer period of time, over the next six-eight months or more, in fact we are looking at levels of about Rs 1,750 plus. But short-term call, I think it's been overdone. I think it's an over reaction to the results. Possibly we should again see the levels of Rs 1,225, sooner than later.

  

Trending News

Business News

Pre-book the Samsung Galaxy S III on Snapdeal for Rs. 250
Did Sebi miss any tricks in Ambani consent order? "Did Sebi miss any tricks in Ambani consent order?"

Karuna's U-turn; 'didn't threaten UPA of pull out'

Dhanlaxmi Bank Q4 NII At `52 Cr

The latest earning numbers FIRST on CNBC-TV18
Videos

May 30 2012, 11:18

Result corner: Ajay Bodke`s top bets from across sectors

- in MARKET OUTLOOK

Interviews

May 30 2012, 17:04 | Source: CNBC-TV18

Margins may be hit on one-off items in EBITDA: Sun Pharma  

May 30 2012, 16:32 | Source: CNBC-TV18

Essar announces Rs 175cr deal; to pay-off debts with fund  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!